Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 3: Rescue therapy outcomes with GP IIb/IIIa inhibitors: IA versus IV administration
Outcome IA GP IIb/IIIa % (95% CI) I² IV GP IIb/IIIa % (95% CI) I² P Value
Postoperative clinical stroke 14.0 (7.0–26.0) 70 14.0 (8.0–26.0) 0 .94
Postoperative infarct on imaging 33.0 (20.0–50.0) 58 23.0 (13.0–36.0) 28 .30
Postoperative hemorrhage 5.0 (3.0–9.0) 0 7.0 (3.0–15.0) 18 .66
Perioperative morbidity from stroke/hemorrhage 10.0 (7.0–15.0) 0 13.0 (6.0–27.0) 34 .57
Perioperative mortality from stroke/hemorrhage 6.0 (4.0–10.0) 0 8.0 (4.0–14.0) 0 .53
Long-term good neurologic outcome 83.0 (76.0–88.0) 0 78.0 (69.0–85.0) 10 .37
Long-term morbidity 14.0 (10.0–21.0) 0 17.0 (11.0–25.0) 2 .56
Recanalization rate 77.0 (66.0–85.0) 58 70.0 (57.0–80.0) 33 .36

Outcome	IA GP IIb/IIIa % (95% CI)	I²	IV GP IIb/IIIa % (95% CI)	I²	P Value
Postoperative clinical stroke	14.0 (7.0–26.0)	70	14.0 (8.0–26.0)	0	.94
Postoperative infarct on imaging	33.0 (20.0–50.0)	58	23.0 (13.0–36.0)	28	.30
Postoperative hemorrhage	5.0 (3.0–9.0)	0	7.0 (3.0–15.0)	18	.66
Perioperative morbidity from stroke/hemorrhage	10.0 (7.0–15.0)	0	13.0 (6.0–27.0)	34	.57
Perioperative mortality from stroke/hemorrhage	6.0 (4.0–10.0)	0	8.0 (4.0–14.0)	0	.53
Long-term good neurologic outcome	83.0 (76.0–88.0)	0	78.0 (69.0–85.0)	10	.37
Long-term morbidity	14.0 (10.0–21.0)	0	17.0 (11.0–25.0)	2	.56
Recanalization rate	77.0 (66.0–85.0)	58	70.0 (57.0–80.0)	33	.36